A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

Fiona C He; Smarika Sapkota; Sarah L Parker; Todd E De For; Erica D Warlick; Celalettin Ustun; Craig E Eckfeldt; Armin Rashidi; Andy Kurtzweil; Daniel J Weisdorf; Nelli Bejanyan

doi:10.1080/10428194.2018.1433297

A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

Fiona C He, Smarika Sapkota, Sarah L Parker, Todd E De For, Erica D Warlick, Celalettin Ustun, Craig E Eckfeldt, Armin Rashidi, Andy Kurtzweil, Daniel J Weisdorf, Nelli Bejanyan

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8–27%) and overall survival (OS) at 2 years was 21% (95% CI 11–33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.

Original language	English (US)
Pages (from-to)	2352-2359
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	59
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2018.1433297
State	Published - Oct 3 2018

Bibliographical note

Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

Ara-c
Clofarabine
acute myeloid leukemia
chemotherapeutic approaches
cytarabine
myeloid leukemias and dysplasias

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1080/10428194.2018.1433297

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839888

OpenUrl availability

Full text

Cite this

@article{bb5cde96257d44abb7d2e91a90960f6d,

title = "A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia",

abstract = "Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8–27%) and overall survival (OS) at 2 years was 21% (95% CI 11–33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.",

keywords = "Ara-c, Clofarabine, acute myeloid leukemia, chemotherapeutic approaches, cytarabine, myeloid leukemias and dysplasias",

author = "He, {Fiona C} and Smarika Sapkota and Parker, {Sarah L} and {De For}, {Todd E} and Warlick, {Erica D} and Celalettin Ustun and Eckfeldt, {Craig E} and Armin Rashidi and Andy Kurtzweil and Weisdorf, {Daniel J} and Nelli Bejanyan",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = oct,

day = "3",

doi = "10.1080/10428194.2018.1433297",

language = "English (US)",

volume = "59",

pages = "2352--2359",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

AU - He, Fiona C

AU - Sapkota, Smarika

AU - Parker, Sarah L

AU - De For, Todd E

AU - Warlick, Erica D

AU - Ustun, Celalettin

AU - Eckfeldt, Craig E

AU - Rashidi, Armin

AU - Kurtzweil, Andy

AU - Weisdorf, Daniel J

AU - Bejanyan, Nelli

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8–27%) and overall survival (OS) at 2 years was 21% (95% CI 11–33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.

AB - Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8–27%) and overall survival (OS) at 2 years was 21% (95% CI 11–33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.

KW - Ara-c

KW - Clofarabine

KW - acute myeloid leukemia

KW - chemotherapeutic approaches

KW - cytarabine

KW - myeloid leukemias and dysplasias

UR - http://www.scopus.com/inward/record.url?scp=85041493093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041493093&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1433297

DO - 10.1080/10428194.2018.1433297

M3 - Article

C2 - 29415603

AN - SCOPUS:85041493093

SN - 1042-8194

VL - 59

SP - 2352

EP - 2359

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this